The association between Lambert-Eaton myasthenic syndrome and small cell lung carcinoma

Immunotherapy in small cell lung cancer: one step at a time: a narrative review

Chemotherapy with or without radiotherapy has been the standard of care for many years for patients with small cell lung cancer (SCLC). Despite exceptionally high responses (up to 80%) with chemotherapy, the majority of patients relapse rapidly within weeks to months after treatment completion. Therefore, new and better treatment options are necessary. Recently, synergistic activity has been reported for the addition of immune checkpoint inhibitors (ICI) to standard platinum-based chemotherapy in the therapeutic strategy of advanced SCLC. For the first time after several decades, a significant survival improvement was achieved for this population. However, the overwhelming majority of patients do not respond to ICI, or relapse rapidly. There is need for better knowledge about the biology, histopathologic features, and molecular pathways of SCLC. This can probably help to identify the optimal predictive biomarkers, which are warranted to develop an individual therapeutic strategy including the rational use of a combination of immunotherapeutic agents. Here, we provide an overview of the rationale for and clinical results of the completed and ongoing trials using different strategies of immunotherapy in SCLC. In addition, opportunities for further improvement of therapies will be discussed, including the addition of radiotherapy, co-stimulatory antibodies, and other immune modifying agents.

A rare case of tuberculosis with motor neuron disease

Motor neuron disease (MND) is occasionally aggravated by chronic infection. A misdiagnosed case of tuberculosis with MND is illustrated in a 45-year-old woman who underwent successful VATS wedge excision, which is presented herein. MND in an adult is a rare clinical entity. In order to facilitate the preoperative diagnosis and avoid the misdiagnosis of this disease, more etiological factors need to be considered.